Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for sub-Saharan Africa (PARCA)

儿童艾滋病毒/艾滋病

• 批准号: 10223896
• 负责人: CARL E ALLEN
• 金额: $ 110.43万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-25 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10223896
• 关键词: AIDS related cancer; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adolescent; Affect; Africa South of the Sahara; African; Biometry; Botswana; Cancer Patient; Caring; Child; Childhood; Clinical Research; Collaborations; Complement; Country; Descriptive Epidemiology; Developmental Diagnostic; Diagnosis; Education; Epidemic; Fellowship; Fellowship Program; Goals; HIV; HIV Infections; HIV diagnosis; Healthcare; Hematological Disease; Hematology; Incidence; Infrastructure; International; Kaposi Sarcoma; Laboratories; Lead; Lymphoma; Malawi; Malignant Childhood Neoplasm; Malignant Neoplasms; Modeling; Oncology; Outcome; Patient-Focused Outcomes; Patients; Pediatric Hematology; Pediatric Hospitals; Pediatric Oncologist; Pediatric Oncology; Pediatric Oncology Group; Research; Research Project Grants; Research Training; Resources; Risk; Risk Factors; Site; Texas; Training; Training Programs; Translational Research; Uganda; Work; base; cancer care; cancer epidemiology; cancer survival; career development; clinical infrastructure; design; improved; improved outcome; infection related cancer; medical specialties; mortality; operation; overtreatment; patient population; pediatric human immunodeficiency virus; pediatric patients; programs; risk stratification; success; training opportunity

Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for Sub-Saharan Africa (PARCA) The goal of this proposal is to establish PARCA, a collaborative clinical and translational research framework designed with the overarching goal to improve the current unacceptably poor outcomes of children with HIV- associated malignancies in sub-Saharan Africa (SSA). Currently, over 80% of children with cancer in the US survive, whereas over 80% in the majority of SSA countries die. To begin to address this disparity and improve outcomes for children with cancer in SSA, Texas Children's Hospital leveraged the clinical infrastructure of BIPAI in Uganda, Malawi, and Botswana to establish Global HOPE (Hematology-Oncology Pediatric Excellence). Global HOPE is dedicated to excellence in the care and treatment of children globally with cancer and blood disorders through state-of-the-art treatments and cutting-edge research. These three Global HOPE pediatric cancer programs, which treat patients nationwide, have begun to transform cancer care in SSA. In the US, improvements in pediatric cancer survival were achieved largely through clinical and translational research coordinated by cooperative groups such as the Children's Oncology Group. Following that model, we propose to establish a framework for collaboration to enable advances for children in SSA living with HIV and diagnosed with cancer through PARCA. The Overarching Goals of the Consortium are to: 1. Define the descriptive epidemiology and infectious exposures related to pediatric malignancies in SSA. We will determine the incidence and outcomes of HIV-associated malignancy across the BIPAI network in SSA. 2. Conduct transformative inter-disciplinary collaborative research to reduce the burden of KS and lymphoma among children and adolescents in SSA. We will establish multi-center strategies for diagnosis, risk- stratification, and outcomes improvement for children with Kaposi sarcoma and lymphoma. These studies will be best conducted in Uganda, Malawi, and Botswana, where the pediatric patient population is large enough to establish meaningful results and conclusions. Validated results will be disseminated throughout our Global HOPE network, as it continues to expand operations in SSA. 3. Support the formation of a multi-national collaborative resource in clinical and translational research, training, and career development for African scientific leaders in HIV and pediatric cancer. We will provide myriad research and training opportunities for pediatric oncologists throughout SSA to participate in and lead translational and clinical research. This program of scientific training will complement and supplement the continued success of Global HOPE Paediatric Haematology and Oncology Fellowship Program.

撒哈拉以南非洲儿童艾滋病毒/艾滋病及感染相关恶性肿瘤研究联盟 (帕卡) 该提案的目标是建立 PARCA，一个协作临床和转化研究框架 其总体目标是改善艾滋病毒感染儿童目前令人难以接受的不良结局 撒哈拉以南非洲（SSA）的相关恶性肿瘤。目前，美国超过 80% 的儿童患有癌症 幸存下来，而大多数 SSA 国家中 80% 以上的人死亡。开始解决这一差距并改进 德克萨斯州儿童医院 SSA 的癌症儿童治疗结果利用了以下临床基础设施： BIPAI 在乌干达、马拉维和博茨瓦纳建立 Global HOPE（儿科血液学-肿瘤学） 卓越）。 Global HOPE 致力于为全球癌症儿童提供卓越的护理和治疗 通过最先进的治疗和尖端研究来治疗和血液疾病。这三个全球希望 为全国患者提供治疗的儿科癌症项目已开始改变 SSA 的癌症护理。在 美国儿童癌症生存率的提高主要是通过临床和转化研究实现的 由儿童肿瘤学组等合作团体协调。遵循该模型，我们建议 建立一个合作框架，以促进撒哈拉以南非洲地区感染艾滋病毒的儿童的福祉，并 通过 PARCA 诊断患有癌症。 该联盟的总体目标是： 1. 定义与 SSA 儿童恶性肿瘤相关的描述性流行病学和感染暴露。我们 将确定 SSA 整个 BIPAI 网络中与 HIV 相关的恶性肿瘤的发病率和结果。 2. 开展变革性跨学科合作研究，减轻 KS 和淋巴瘤的负担 SSA 的儿童和青少年。我们将建立多中心诊断、风险评估策略 卡波西肉瘤和淋巴瘤儿童的分层和结果改善。这些研究 最好在乌干达、马拉维和博茨瓦纳进行，这些地方的儿科患者人数较多 足以建立有意义的结果和结论。验证结果将在整个范围内传播 我们的全球 HOPE 网络，继续扩大在 SSA 的业务。 3. 支持在临床和转化研究方面形成跨国合作资源， 为非洲艾滋病毒和儿科癌症领域的科学领袖提供培训和职业发展。我们将提供 为整个 SSA 的儿科肿瘤学家提供大量研究和培训机会，让他们参与和 领导转化和临床研究。这一科学培训计划将补充和补充 全球 HOPE 儿科血液学和肿瘤学奖学金计划的持续成功。